Our expertise ranges across many industries, products and technologies, our recent focus has been on the emerging Cannabinoid research and product markets. This exciting market is already worth £300m in the UK alone and is expected to be £1bn by 2025. Globally the market is expected to continue to grow at over 30% per annum from its current value of £8bn.
Our focus is on maximising shareholder value by ensuring you do the right thing and to try to stop you doing the wrong thing. In emerging and disruptive markets there are many great ideas, but not all are commercially viable, and each carries its own intrinsic risk. Our objective is to ensure you have the right strategy and the right team to deliver the returns you expect from your investment while cognoscente of your appetite for risk. This is particularly pertinent during the Pandemic; we will even hold your hand if its time to exit your investment.
Our advice considers multiple factors including market insights, the core science & technology, regulatory frameworks, the resources and risks associated with scaling the business, the skills of the existing management, shareholder motivations, and market factors.